阿托伐他汀强化治疗对冠状动脉血流缓慢综合征患者的影响

被引：7

作者：

梁健球 ^{[1
,2
]}

吴剑弟 ^{[3
]}

黄永光 ^{[3
]}

王玉燕 ^{[3
]}

欧小敏 ^{[3
]}

许顶立 ^{[1
]}

机构：

[1] 南方医科大学南方医院心血管内科

[2] 佛山第二人民医院心内科

[3] 佛山市第二人民医院心内科ICU

来源：

中华老年心脑血管病杂志 | 2012年 / 14卷 / 05期

关键词：

冠状动脉疾病; 血流速度; 冠状血管造影术; 胆固醇,LDL; 胆固醇,HDL; C反应蛋白质; 血管细胞黏附分子1;

D O I：

暂无

中图分类号：

R543.3 [冠状动、静脉疾病];

学科分类号：

1002 ; 100201 ;

摘要：

目的观察阿托伐他汀强化治疗对冠状动脉血流缓慢(SCF)综合征患者的影响。方法选择28例经冠状动脉造影确诊为SCF综合征的患者为SCF组,口服阿托伐他汀40 mg/d,25例冠状动脉血流正常(NCF)患者作为NCF组。治疗前后,分别检测2组TC、LDL-C、HDL-C、高敏C反应蛋白(hs-CRP)、细胞间黏附分子1(ICAM-1)、血管细胞黏附分子1(VCAM-1)、E选择素;采用超声检测肱动脉血流介导的内皮依赖性血管舒张功能(FMD)和硝酸甘油治疗的非内皮依赖性血管舒张功能(NMD),以冠状动脉血流计帧值法(Timi-FC)评价造影时冠状动脉血流速度。结果与治疗前比较,治疗4周后SCF组Timi-FC、TC、LDL-C、hs-CRP、ICAM-1、VCAM-1及E选择素显著降低(P<0.05),FMD及NMD显著升高(P<0.01);与NCF组比较,hs-CRP、ICAM-1、VCAM-1、E选择素、FMD及NMD无显著差异;与治疗前比较,NCF组随访4周后TC、LDL-C显著降低(P<0.05);Timi-FC与hs-CPC、ICAM-1、VCAM-1和E选择素呈正相关(P<0.01),与FMD、NMD呈负相关(P<0.01)。结论 SCF与血管内皮功能及炎性反应密切相关,他汀类药物强化治疗可降低炎性反应,改善血管内皮功能,提高冠状动脉血流速度。

引用

页码：460 / 463

页数：4

共 16 条

[1] Vascular endothelial function in patients with slow coronary flow [J].

Sezgin, AT ;

Sigirci, A ;

Barutcu, I ;

Topal, E ;

Sezgin, N ;

Ozdemir, R ;

Yetkin, E ;

Tandogan, I ;

Kosar, F ;

Ermis, N ;

Yologlu, S ;

Bariskaner, E ;

Cehreli, S .

CORONARY ARTERY DISEASE, 2003, 14 (02) :155-161

[2]

Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow. CalistKan M,Erdogan D,Gullu H,et al. Clinical Cardiology . 2007

[3]

Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery[J] . Mary C Corretti,Todd J Anderson,Emelia J Benjamin,David Celermajer,Francois Charbonneau,Mark A Creager,John Deanfield,Helmut Drexler,Marie Gerhard-Herman,David Herrington,Patrick Vallance,Joseph Vita,Robert Vogel. &nbspJournal of the American College of Cardiology . 2002 (2)

[4] G-CSF exerts dual effects on endothelial cells-Opposing actions of direct eNOS induction versus indirect CRP elevation [J].

Park, Kyung-Woo ;

Kwon, Yoo-Wook ;

Cho, Hyun-Jai ;

Shin, Jung-Im ;

Kim, Yong-Jin ;

Lee, Sang Eun ;

Youn, Seock-Won ;

Lee, Hyun-Chae ;

Kang, Hyun-Jae ;

Shaul, Philip W. ;

Oh, Byung-Hee ;

Park, Young-Bae ;

Kim, Hyo-Soo .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 45 (05) :670-678

[5]

Protection From Procedural Myocardial Injury by Atorvastatin Is Associated With Lower Levels of Adhesion Molecules After Percutaneous Coronary Intervention[J] . Giuseppe Patti,Massimo Chello,Vincenzo Pasceri,Diego Colonna,Annunziata Nusca,Marco Miglionico,Andrea D’Ambrosio,Elvio Covino,Germano Di Sciascio. &nbspJournal of the American College of Cardiology . 2006 (8)

[6]

A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22[J] . Stephen D. Wiviott,James A. de Lemos,Christopher P. Cannon,Michael Blazing,Sabina A. Murphy,Carolyn H. McCabe,Robert Califf,Eugene Braunwald. &nbspCirculation . 2006 (11)

[7]

Vascular endothelial function in patients with slow coronary flow. Sezgin AT,Sigirci A,Barutcu I,et al. Coronary Artery Disease . 2003

[8]

Atrovastatin use and cor-onary flow reserve in patients with coronary slow flow. Fan Y,Yang S S,Yu J B,et al. Zhonghua Xin Xue Guan Bing Za Zhi . 2010

[9]

G-CSF exerts dual effects on endothelial cells--opposing actions of direct eNOS induction versus indirect CRP elevation. Park KW,Kwon YW,Cho HJ,et al. Journal of Molecular and Cellular Cardiology . 2008

[10]

Atale of two trials:a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI22. Wiviott SD,de Lemos JA,Cannon CP,et al. Circulation . 2006

← 1 2 →